These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 35968344)

  • 21. Nuclear Localization of BRAF
    Zerfaoui M; Toraih E; Ruiz E; Errami Y; Attia AS; Krzysztof M; Abd Elmageed ZY; Kandil E
    Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053476
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcome.
    Guerra A; Fugazzola L; Marotta V; Cirillo M; Rossi S; Cirello V; Forno I; Moccia T; Budillon A; Vitale M
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2333-40. PubMed ID: 22508706
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinicopathologic correlations of the BRAFV600E mutation, BRAF V600E immunohistochemistry, and BRAF RNA in situ hybridization in papillary thyroid carcinoma.
    Jung YY; Yoo JH; Park ES; Kim MK; Lee TJ; Cho BY; Chung YJ; Kang KH; Ahn HY; Kim HS
    Pathol Res Pract; 2015 Feb; 211(2):162-70. PubMed ID: 25468810
    [TBL] [Abstract][Full Text] [Related]  

  • 24. BRAFV600E mutation and X-linked inhibitor of apoptosis expression in papillary thyroid carcinoma.
    Gu LQ; Li FY; Zhao L; Liu Y; Zang XX; Wang TX; Chen HP; Ning G; Zhao YJ
    Thyroid; 2009 Apr; 19(4):347-54. PubMed ID: 19355825
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF V600E mutation co-existing with oncogenic mutations is associated with aggressive clinicopathologic features and poor prognosis in papillary thyroid carcinoma.
    Bandoh N; Goto T; Kato Y; Kubota A; Sakaue S; Takeda R; Hayashi S; Hayashi M; Baba S; Yamaguchi-Isochi T; Nishihara H; Kamada H
    Asian J Surg; 2024 Jan; 47(1):413-419. PubMed ID: 37752023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Diagnosis of High-Risk Papillary Thyroid Carcinoma Using Ultrasound Contrast Agent With the BRAF
    Xie F; Yan L; Li YM; Lan Y; Xiao J; Zhang MB; Jin Z; Zhang Y; Tian XQ; Zhu YQ; Li ZP; Luo YK
    J Ultrasound Med; 2022 Nov; 41(11):2789-2802. PubMed ID: 35229905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Associations of the BRAF V600E Mutation and PAQR3 Protein Expression with Papillary Thyroid Carcinoma Clinicopathological Features.
    Gao J; Ma XP; Deng FS; Jiang L; Jia WD; Li M
    Pathol Oncol Res; 2020 Jul; 26(3):1833-1841. PubMed ID: 31758408
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MUC1 expression in papillary thyroid carcinoma is associated with BRAF mutation and lymph node metastasis; the latter is the most important risk factor of relapse.
    Renaud F; Gnemmi V; Devos P; Aubert S; Crépin M; Coppin L; Ramdane N; Bouchindhomme B; d'Herbomez M; Van Seuningen I; Do Cao C; Pattou F; Carnaille B; Pigny P; Wémeau JL; Leteurtre E
    Thyroid; 2014 Sep; 24(9):1375-84. PubMed ID: 25012490
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Frequency and Clinical Implications of the BRAF(V600E) Mutation in Papillary Thyroid Cancer Patients in Korea Over the Past Two Decades.
    Hong AR; Lim JA; Kim TH; Choi HS; Yoo WS; Min HS; Won JK; Lee KE; Jung KC; Park DJ; Park YJ
    Endocrinol Metab (Seoul); 2014 Dec; 29(4):505-13. PubMed ID: 25325273
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation.
    Kim KB; Cabanillas ME; Lazar AJ; Williams MD; Sanders DL; Ilagan JL; Nolop K; Lee RJ; Sherman SI
    Thyroid; 2013 Oct; 23(10):1277-83. PubMed ID: 23489023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF
    Gao Y; Xiang D; Li W; Zheng X; Wang L; Li Z; Chen T
    Front Endocrinol (Lausanne); 2022; 13():843334. PubMed ID: 35651980
    [No Abstract]   [Full Text] [Related]  

  • 33. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
    Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
    Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Associations of the BRAF (V600E) mutation and p53 protein expression with clinicopathological features of papillary thyroid carcinomas patients.
    Shin MK; Kim JW; Min SK; Lee DJ; Kim JH; Lee SC; Chung BW; Ju YS
    Oncol Lett; 2015 Sep; 10(3):1882-1888. PubMed ID: 26622769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
    Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
    Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association between expression of X-linked inhibitor of apoptosis protein and the clinical outcome in a BRAF V600E-prevalent papillary thyroid cancer population.
    Yim JH; Kim WG; Jeon MJ; Han JM; Kim TY; Yoon JH; Hong SJ; Song DE; Gong G; Shong YK; Kim WB
    Thyroid; 2014 Apr; 24(4):689-94. PubMed ID: 24124924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality.
    Liu R; Bishop J; Zhu G; Zhang T; Ladenson PW; Xing M
    JAMA Oncol; 2017 Feb; 3(2):202-208. PubMed ID: 27581851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of BRAF V600E mutation as a potential marker for prognostic stratification of papillary thyroid carcinoma: a long-term follow-up study.
    Daliri M; Abbaszadegan MR; Bahar MM; Arabi A; Yadollahi M; Ghafari A; Taghehchian N; Zakavi SR
    Endocr Res; 2014; 39(4):189-93. PubMed ID: 24679337
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer.
    Celik M; Bulbul BY; Ayturk S; Durmus Y; Gurkan H; Can N; Tastekin E; Ustun F; Sezer A; Guldiken S
    Med Glas (Zenica); 2020 Feb; 17(1):30-34. PubMed ID: 31994851
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRAFV600E mutation does not serve as a prognostic factor in Korean patients with papillary thyroid carcinoma.
    Ahn D; Park JS; Sohn JH; Kim JH; Park SK; Seo AN; Park JY
    Auris Nasus Larynx; 2012 Apr; 39(2):198-203. PubMed ID: 21862261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.